Akebia Therapeutics

About:

Akebia Therapeutics develops treatments for ischemia and vascular diseases.

Twitter/X: akebiatx

Top Investors: BlackRock, Novo Holdings, CincyTech, Novartis Venture Fund, Pharmakon Advisors

Description:

Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolyl hydroxylase enzyme and phosphatase enzyme. Akebia Therapeutics, Inc. was founded in 2007 and is based in Cincinnati, Ohio.

Total Funding Amount:

$443M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2007-01-01

Contact Email:

info(AT)akebia.com

Founders:

Joseph Gardner, Robert Shalwitz

Number of Employees:

101-250

Last Funding Date:

2024-01-30

IPO Status:

Public

Industries:

Biotechnology

Health Care

Therapeutics